Although most national and international guidelines currently recommend testing for EGFR mutations and ALK gene rearrangements [3–5], it is becoming increasingly clear that more extensive analysis of a tumor's genetic profile is critical to identifying mutations or gene fusions sensitive to already approved therapies but not detected by hotspot testing methods [6]. This evidence concerns the gene ALK and neoplasm.